KansasPrescribed does not mean approved

A little clarity before care.

All chapters

What this record can establish

Look for evidence that answers your question.

A source can be real and still answer the wrong question. A licence, a study, a drug label and a rule each tell you something different.

Start with the short answer
Follow the question.
  1. LicenceA person’s public status
  2. ApprovalAn exact product record
  3. Study or adviceRead its scope and limits

Reconsider the care assumption

Read what kind of record it is.

Federal evidence and regulatory status as of September 26, 2026.

NDC stands for National Drug Code: the product code used in a drug directory. The Food and Drug Administration (FDA) says a code or listing does not prove approval.

Ask for the actual approval record for the exact product, rather than a screenshot of a code.

Read the scope of each record

Match the evidence to the claim

For the person: check if the licence remains current, then look for any board-listed penalties, restrictions or pending disciplinary charges. That record does not rate the quality of care.

For the product: find out whether it has approval or was prepared to order. A compounded preparation has not had the same FDA product review.

For a study: ask whether it tested this exact product, how it was used, what it found, and what it did not answer. A familiar ingredient name is not enough detail.

For a rule: look for the current text and the date it took effect. A proposed change is not the same as a rule in force.

A meeting does not change permission by itself

An FDA advisory committee is a group formed to advise the agency. Its vote cannot add an ingredient to the official list of extra ingredients allowed for medicines made for a named patient. FDA must complete the formal process for changing that rule.

That list is one part of the ingredient rules. Other routes depend on an ingredient’s written quality standard or use in an approved drug. Ask which rule covers your exact ingredient; a meeting headline does not answer that question.

At the September 2026 check, FDA had not published minutes, a transcript or an official vote record for its July peptide meeting.

A headline about that meeting is not proof that a peptide has become permitted to compound.

Read a letter with its limits

FDA warning letters state possible rule violations at a point in time. Later exchanges with the recipient may change the position.

No letter does not prove that a company passed a check. It may not have been reviewed.

Ask which source supports the claim you are hearing, what its date is, and whether the exact product appears in it.

Take this with you

Words to start the conversation

  • Does the source cover this exact medicine as a pill, injection or other kind?
  • Does the record show approval, a listing, advice or a proposed change?
  • What remains unanswered by that source?

Chapter notes

Evidence for this chapter

  1. A
    FDA: National Drug Code directory limits

    For why a product code does not prove approval.

  2. B
    FDA: medicine approval records

    For finding the exact medicine’s approval record and matching its pill or injection version. Ask a pharmacist to help read the record if needed.

  3. C
    FDA: compounded medicine review

    For what has and has not been checked.

  4. D
    FDA: peptide advisory meeting materials

    For the official meeting record available at the stated date.

  5. E
    FDA: compounding ingredient decisions

    For the ingredient rules and the formal process to change the extra-ingredient list.

  6. F
    FDA: search letters about rule violations

    For the dated letter, the company’s reply and any later FDA letter about how the concerns were addressed. Read what each letter actually concludes.